Zaneta Bulaj, MD
Internal Medicine · Salt Lake City, UTNPI 1598869026
Payments from drug & device makers
Across 88 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$265
- Abbott$161
- Merck$124
- Lilly USA, LLC$113
- GSK$106
- Novo Nordisk$89
- plus $714 from 23 others
What the payments were for
- Food & beverage$1,572100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $265 |
| Abbott | 8 | $161 |
| Merck | 7 | $124 |
| Lilly USA, LLC | 7 | $113 |
| GSK | 7 | $106 |
| Novo Nordisk | 5 | $89 |
| Astellas Pharma US Inc | 4 | $82 |
| Boston Scientific | 6 | $81 |
| Pfizer | 5 | $81 |
| AstraZeneca | 5 | $65 |
| Bayer | 3 | $59 |
| Viiv Healthcare Company | 2 | $40 |
| Dexcom, Inc. | 2 | $25 |
| Recor Medical Inc | 1 | $22 |
| Amgen | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| CMP Pharma, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Novartis | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Avion Pharmaceuticals | 1 | $12 |
| Medtronic | 1 | $11 |
How this compares
$1,572 in reported general payments places this provider in the 75th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 194 | $223,169 |
| EliquisApixaban | 140 | $117,657 |
| MounjaroTirzepatide | 88 | $99,716 |
| TrulicityDulaglutide | 50 | $78,446 |
| FarxigaDapagliflozin Propanediol | 82 | $75,380 |
| JardianceEmpagliflozin | 61 | $74,789 |
| XareltoRivaroxaban | 44 | $41,465 |
| MyrbetriqMirabegron | 39 | $36,921 |
| JanuviaSitagliptin Phosphate | 29 | $29,416 |
| RybelsusSemaglutide | 14 | $28,589 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $25,371 |
| Spiriva RespimatTiotropium Bromide | 19 | $21,770 |
| LinzessLinaclotide | 35 | $18,662 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $17,032 |
| Levothyroxine Sodium | 936 | $9,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $89 | $251,758208 claims |
| Lilly USA, LLCMounjaro, Trulicity | $113 | $178,162138 claims |
| PfizerEliquis | $81 | $117,657140 claims |
| AstraZenecaFarxiga, Symbicort | $65 | $81,263102 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $82 | $44,32351 claims |
| Johnson & JohnsonXarelto | $18 | $41,46544 claims |
| MerckJanuvia | $124 | $29,41629 claims |
| GSKTrelegy Ellipta | $106 | $25,37125 claims |
| AbbVieLinzess | $265 | $18,66235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Salt Lake City
- Ahad SabetSalt Lake City$34.5M
- Willard DereSalt Lake City$4.7M
- Brandon WebbSalt Lake City$544K
- Larry StakerSalt Lake City$441K
- Alexander PastuszakSalt Lake City$197K
- Lowell BensonSalt Lake City$183K
- Gerald GleichSalt Lake City$119K
- James ChamberlainSalt Lake City$106K
- Zameer AbedinSalt Lake City$83K
- Brian HornerSalt Lake City$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.